Context Therapeutics (NASDAQ:CNTX – Get Rating) is one of 994 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Context Therapeutics to similar businesses based on the strength of its institutional ownership, risk, earnings, dividends, profitability, valuation and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Context Therapeutics and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Context Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
| Context Therapeutics Competitors | 4276 | 15179 | 41688 | 723 | 2.63 |
Context Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 555.74%. As a group, “Pharmaceutical preparations” companies have a potential upside of 104.18%. Given Context Therapeutics’ higher probable upside, analysts plainly believe Context Therapeutics is more favorable than its rivals.
Risk & Volatility
Valuation & Earnings
This table compares Context Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Context Therapeutics | N/A | -$14.84 million | -0.66 |
| Context Therapeutics Competitors | $1.81 billion | $240.74 million | -3.42 |
Context Therapeutics’ rivals have higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Context Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Context Therapeutics | N/A | -37.12% | -34.55% |
| Context Therapeutics Competitors | -3,408.21% | -234.50% | -35.37% |
Institutional & Insider Ownership
25.9% of Context Therapeutics shares are owned by institutional investors. Comparatively, 40.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 6.7% of Context Therapeutics shares are owned by company insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Context Therapeutics rivals beat Context Therapeutics on 7 of the 13 factors compared.
About Context Therapeutics
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
